MDxHealth Discontinues Resolve UTI Test Amid Reimbursement Challenges in Q1 2026
MDxHealth reported its first-quarter 2026 financial results, highlighting a strategic shift to focus exclusively on its core prostate cancer diagnostics business. The company announced the discontinuation of its Resolve UTI offering and the closure of its Plano, Texas laboratory facility. This decision stems from an increasingly uncertain reimbursement landscape, specifically citing a policy reversal by Novitas, the Medicare Administrator for Texas, which seeks to recoup $10.4 million in historical claims. MDxHealth is vigorously defending against this recoupment through formal appeals. By exiting the volatile UTI market, the company aims to redirect capital and sales efforts toward its prostate cancer portfolio, including Confirm, GPS, and the recently acquired ExoDx business. The integration of ExoDx is progressing well, with completed sales force training and customer transitions. Additionally, MDxHealth is leveraging artificial intelligence to enhance operational efficiency and clinical value, notably through the PROTECT trial with the University of Oxford. This strategic refocus is intended to solidify MDxHealth's position as a leader in urology precision diagnostics while ensuring long-term financial sustainability and operating discipline.
Editorial responsibility
- No named human review is recorded for this page.
- Reports are grouped by semantic similarity and deterministic rules. Language models may assist titles, summaries, translation and cross-source analysis; the page itself is projected from evidence records.
- Current automated evidence projection